Citi analyst Vineet Agrawal initiated coverage of Sandoz with a Buy rating and CHF 35 price target. The analyst sees Sandoz as well positioned to capture value from a 20%-plus growing biosimilars market driven by its five high-potential pipeline products also aiding margin expansion.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SDZNY: